



Update from NRS Reproductive Health and Childbirth Specialty Group July 2022



*The world's first baby to be conceived via IVF was Louise Joy Brown,
born 25th July 1978, Royal Oldham Hospital*



LOCI UPDATE FROM THE TRIAL TEAM

Letrozole **O**r Clomifene for Ovulation **I**nduction. CPMS 42795, IRAS 257918.
Chief Investigator: Professor Arri Coomarasamy, University of Birmingham.

Current clinical guidelines in the UK recommend the use of clomifene with or without another medicine, metformin, for ovulation induction in women who suffer from polycystic ovary syndrome (PCOS). Recently there has been growing interest in the use of another medicine, letrozole, to treat infertility in women with PCOS. Letrozole works differently to clomifene and has fewer side effects, including a lower risk of multiple pregnancy. A recent review of studies involving all available medicines for women with PCOS and infertility has indicated that letrozole may be more effective than clomifene when used alone, and there may be additional value when it is combined with metformin.

The LOCI trial is a 2x2 factorial trial to test whether letrozole (with or without metformin) for ovulation induction in women with PCOS increases the number of successful live births in comparison to clomifene (with or without metformin). The trial has been recruiting since November 2020, and there are currently 803 out of 2100 participants. In Scotland, the following hospitals have recruited to the trial: Aberdeen Fertility Centre, Glasgow Royal Infirmary, Royal Infirmary Edinburgh, and University Hospital Crosshouse.

The LOCI team are extremely grateful for everyone's efforts to recruit participants to this study and help us answer this important clinical question.

SURVEY:

Contribution to the development of the SPIRIT-SURROGATE and CONSORT-SURROGATE extensions



The SPIRIT | CONSORT-SURROGATE Project Team would like to ask for your contribution to the MRC funded project that is developing reporting guidelines for randomised controlled trials (RCTs) protocols and reports using surrogate primary endpoints: the SPIRIT-SURROGATE and CONSORT-SURROGATE extensions.



By taking part in their survey, you will help them to develop guidelines for reporting RCTs with surrogate primary endpoints. The survey will ask for your views on the **most important items that should be reported by RCTs reports and protocols using surrogate endpoints**. Full document [here](#). For more information about this project please visit the [website](#).

You can register your interest to participate using this link: <https://forms.office.com/r/1UuDCBU8bc>

Contacts:

Abha (abha.maheshwari@abdn.ac.uk), NRS Clinical Research Lead, or
Txaro (maria.amezaga@nhs.scot), NRS Champion Support Manager

Please keep sending us your Good News Stories!

Which good news stories do your teams have to share?

First patients to Trials, completion of difficult Trials to Target, Key Studies, Findings, Awards/achievements of local PI/CI/team members, collaborations, working with NIHR in cross border studies, bringing/ opening of Trials in Scotland.

Anything that goes on behind the scenes of recruitment numbers, overcoming challenges, achievements, etc.

STUDIES RECENTLY OPENED IN SCOTLAND

STOP-OHSS. Shaping and Trialling Outpatient Protocols for Ovarian HyperStimulation Syndrome: A randomised controlled trial to assess the clinical and cost-effectiveness of active management of Ovarian HyperStimulation Syndrome.



CPMS ID 51579, IRAS 298619. CI: Mr Mostafa Metwally, Sheffield Teaching Hospitals. Funder: NIHR.

DIAMOND. Deep infiltrating endometriosis: management by medical treatment versus early surgery.



CPMS ID 52443, IRAS 298771. CIs: Professors Kevin Cooper, Aberdeen Royal Infirmary and T Justin Clark, Birmingham Women's NHS Foundation Trust. Funder NIHR HTA.

Featured in the June newsletter.

STOPPIT-M. A mechanism of action of health intervention study. Infant hypothalamic-pituitary-adrenal axis responses following antenatal corticosteroids and perinatal outcomes.



CPMS ID 52586, IRAS 309594. CI: Professor Rebecca Reynolds, University of Edinburgh. Funder: NIHR (NETSCC).

